P.2.083 Pilot study of the effects of rivastigmine in schizophrenia

Graaff, K.M. Van de; Loonen, Anton J. M.; Hovens, Johannes E.; Dijke, A. van; Tulen, Joke H.M.

doi:10.1016/s0924-977x(03)92036-0

European Neuropsychopharmacology

2003

DOI: 10.1016/s0924-977x(03)92036-0

|View full text |Cite

P.2.083 Pilot study of the effects of rivastigmine in schizophrenia

K.M. Van de Graaff¹,

Anton J. M. Loonen²,

Johannes E. Hovens³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2005

2007

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Oral Cholinesterase Inhibitor Add-on Therapy for Cognitive Enhancement in Schizophrenia

Chouinard¹,

Sepehry²,

Stip³

2007

Clinical Neuropharmacology

View full text Add to dashboard Cite

Despite an extensive investigation of the electronic and gray literature, few data appropriate for the meta-analysis were found. The results reveal a small improvement in attention and a trend on motor tasks after AChEI medication in schizophrenia. No clear conclusion can yet be reached concerning the cognitive-enhancing effects of AChEI considering the small number of studies available. This finding needs to be substantiated by larger trials. This systematic review complements a meta-analysis focusing on memory, which showed a small improvement with a cocktail of antipsychotics and AChEIs.

show abstract

Oral Cholinesterase Inhibitor Add-on Therapy for Cognitive Enhancement in Schizophrenia

Chouinard¹,

Sepehry²,

Stip³

2007

Clinical Neuropharmacology

View full text Add to dashboard Cite

show abstract

Effects of Rivastigmine in a Case of Residual Schizophrenia

2005

View full text Add to dashboard Cite

Aripiprazole is a new-generation atypical antipsychotic agent. It is a partial agonist at the dopamine D 2 and serotonin 1A (5-HT 1A) receptor sites; it is an antagonist at the 5-HT 2 receptor site (1). Data from the aripiprazole clinical trials suggest that the drug may reduce serum prolactin levels (2). However, we have observed a case of raised serum prolactin and galactorrhea in association with aripiprazole. To the best of our knowledge, this is the first case of aripiprazole-induced galactorrhea in world literature. Case Report Mrs S, aged 36 years, presented with a 2-month history of suspiciousness, withdrawal, and neglect of personal care. She fulfilled DSM-IV criteria for schizophreniform disorder. She was drug-naive for the episode, and was prescribed aripiprazole in a dosage that was titrated from 10 mg daily to 15 mg daily over a period of 2 weeks. At week 3 of aripriprazole therapy, she developed tremor, rigidity, salivation, and bradykinesia, along with simultaneous breast tenderness and a milky discharge from the nipples. Her serum prolactin was found to be elevated to 27 ng/mL (normal range, 1.5 to 19.0 ng/mL). All other investigations, including thyroid profile and brain CT scan, were normal.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

P.2.083 Pilot study of the effects of rivastigmine in schizophrenia

Cited by 2 publications

References 0 publications

Oral Cholinesterase Inhibitor Add-on Therapy for Cognitive Enhancement in Schizophrenia

Oral Cholinesterase Inhibitor Add-on Therapy for Cognitive Enhancement in Schizophrenia

Effects of Rivastigmine in a Case of Residual Schizophrenia

Contact Info

Product

Resources

About